On September 3, the office building of Gansu HPMC Innovation Technology Co., Ltd., a subsidiary of Shanghai Unicornshell Pharmaceutical Technology Co., Ltd., was successfully topped out, and a grand topping‑out ceremony was held. Attendees included all members of the Shandan Project Company, the supervision unit, and the general construction contractor. Gansu HPMC Innovation Technology Co., Ltd. is located in Shandan County, Zhangye City, and is an important part of Unicornshell's Northwest China industrial cluster layout. The successful topping out of the office building marks the project's transition from the main construction phase to the secondary structure and finishing decoration phases, laying a solid foundation for subsequent production workshop construction and trial production.

At the topping‑out ceremony, all construction parties gave high praise to the project's progress, noting that the topping out of the office building represented a phased achievement. They stated that they would continue to advance the subsequent construction of production workshops and related supporting facilities according to the planned schedule, and all parties would make every effort to accelerate progress, ensuring the project is fully completed on schedule and striving for early mass production and operation.

Unicornshell upholds its corporate mission of "promoting medication safety and protecting human health" and focuses on the R&D of HPMC pharmaceutical excipients. The company uses non‑animal raw materials such as plant cellulose and potato starch, combined with proprietary patented processes, to develop HPMC capsules and a series of products. These products offer high safety, good biocompatibility, and excellent stability, and can be widely used in pharmaceuticals, health products, and food — serving as an ideal alternative to gelatin capsules.

In addition, Unicornshell's strategic focus is a "two‑pronged approach": on one hand, making continuous breakthroughs in the HPMC capsule field to provide green, safe, and internationally compliant excipient solutions; on the other hand, leveraging Gansu's high‑quality authentic medicinal herbs to develop innovative TCM orally dissolving film tablets, expanding new application scenarios for traditional TCM formulations. This dual‑engine drive not only supports the modernization of TCM but also highlights the strategic value of Gansu's medicinal herb resources in the company's national layout.

The smooth progress of the Gansu project will provide strong support for the construction of Unicornshell's Northwest China industrial cluster, while laying a solid foundation for nationwide industrial network synergy, product system improvement, and market expansion. Unicornshell will continue to adhere to its development strategy of "green, safe, and intelligent", promote the upgrading of the green pharmaceutical industry, and contribute to global health.